What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?

Vikki M. Abrahams, Maria O. Borghi, Pier Luigi Meroni, Jacob H. Rand, ElenA Raschi, Jane E. Salmon, Francesco Tedesco, AngelA Tincani

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Pregnancy complications are a frequent and unsolved condition in patients with antiphospholipid syndrome (APS). Women with antiphospholipid antibodies (aPL) are at high risk of recurrent early pregnancy loss, as well as late obstetrical complications associated with impaired placental function, such as preeclampsia, intrauterine growth restriction, and prematurity. Thrombotic events at the maternal–fetal interface were originally thought to underlie aPL-associated pregnancy complications, due to the partial beneficial effects of heparin. However, more recent clinical and experimental observations suggest, instead, that non-thrombotic events may play a primary role in the pathophysiology of pregnancy complications in APS patients, including complement activation, inflammation, and disruption of normal trophoblast function. This chapter will review the known pathogenic mechanisms of pregnancy complications in APS and provide a helpful instrument to all the workers in the field from both a clinical and basic view.

Original languageEnglish
Title of host publicationAntiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies
PublisherSpringer US
Pages79-101
Number of pages23
ISBN (Print)9781461431947, 9781461431930
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Antiphospholipid Antibodies
Pregnancy Complications
Antiphospholipid Syndrome
Morbidity
Pregnancy
Complement Activation
Trophoblasts
Pre-Eclampsia
Health Personnel
Heparin
Inflammation
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abrahams, V. M., Borghi, M. O., Meroni, P. L., Rand, J. H., Raschi, E., Salmon, J. E., ... Tincani, A. (2012). What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity? In Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies (pp. 79-101). Springer US. https://doi.org/10.1007/978-1-4614-3194-7_5

What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity? / Abrahams, Vikki M.; Borghi, Maria O.; Meroni, Pier Luigi; Rand, Jacob H.; Raschi, ElenA; Salmon, Jane E.; Tedesco, Francesco; Tincani, AngelA.

Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, 2012. p. 79-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abrahams, VM, Borghi, MO, Meroni, PL, Rand, JH, Raschi, E, Salmon, JE, Tedesco, F & Tincani, A 2012, What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity? in Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, pp. 79-101. https://doi.org/10.1007/978-1-4614-3194-7_5
Abrahams VM, Borghi MO, Meroni PL, Rand JH, Raschi E, Salmon JE et al. What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity? In Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US. 2012. p. 79-101 https://doi.org/10.1007/978-1-4614-3194-7_5
Abrahams, Vikki M. ; Borghi, Maria O. ; Meroni, Pier Luigi ; Rand, Jacob H. ; Raschi, ElenA ; Salmon, Jane E. ; Tedesco, Francesco ; Tincani, AngelA. / What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?. Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, 2012. pp. 79-101
@inbook{2cb15c58192c4be0a07014c839aa2531,
title = "What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?",
abstract = "Pregnancy complications are a frequent and unsolved condition in patients with antiphospholipid syndrome (APS). Women with antiphospholipid antibodies (aPL) are at high risk of recurrent early pregnancy loss, as well as late obstetrical complications associated with impaired placental function, such as preeclampsia, intrauterine growth restriction, and prematurity. Thrombotic events at the maternal–fetal interface were originally thought to underlie aPL-associated pregnancy complications, due to the partial beneficial effects of heparin. However, more recent clinical and experimental observations suggest, instead, that non-thrombotic events may play a primary role in the pathophysiology of pregnancy complications in APS patients, including complement activation, inflammation, and disruption of normal trophoblast function. This chapter will review the known pathogenic mechanisms of pregnancy complications in APS and provide a helpful instrument to all the workers in the field from both a clinical and basic view.",
author = "Abrahams, {Vikki M.} and Borghi, {Maria O.} and Meroni, {Pier Luigi} and Rand, {Jacob H.} and ElenA Raschi and Salmon, {Jane E.} and Francesco Tedesco and AngelA Tincani",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-3194-7_5",
language = "English",
isbn = "9781461431947",
pages = "79--101",
booktitle = "Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies",
publisher = "Springer US",

}

TY - CHAP

T1 - What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?

AU - Abrahams, Vikki M.

AU - Borghi, Maria O.

AU - Meroni, Pier Luigi

AU - Rand, Jacob H.

AU - Raschi, ElenA

AU - Salmon, Jane E.

AU - Tedesco, Francesco

AU - Tincani, AngelA

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Pregnancy complications are a frequent and unsolved condition in patients with antiphospholipid syndrome (APS). Women with antiphospholipid antibodies (aPL) are at high risk of recurrent early pregnancy loss, as well as late obstetrical complications associated with impaired placental function, such as preeclampsia, intrauterine growth restriction, and prematurity. Thrombotic events at the maternal–fetal interface were originally thought to underlie aPL-associated pregnancy complications, due to the partial beneficial effects of heparin. However, more recent clinical and experimental observations suggest, instead, that non-thrombotic events may play a primary role in the pathophysiology of pregnancy complications in APS patients, including complement activation, inflammation, and disruption of normal trophoblast function. This chapter will review the known pathogenic mechanisms of pregnancy complications in APS and provide a helpful instrument to all the workers in the field from both a clinical and basic view.

AB - Pregnancy complications are a frequent and unsolved condition in patients with antiphospholipid syndrome (APS). Women with antiphospholipid antibodies (aPL) are at high risk of recurrent early pregnancy loss, as well as late obstetrical complications associated with impaired placental function, such as preeclampsia, intrauterine growth restriction, and prematurity. Thrombotic events at the maternal–fetal interface were originally thought to underlie aPL-associated pregnancy complications, due to the partial beneficial effects of heparin. However, more recent clinical and experimental observations suggest, instead, that non-thrombotic events may play a primary role in the pathophysiology of pregnancy complications in APS patients, including complement activation, inflammation, and disruption of normal trophoblast function. This chapter will review the known pathogenic mechanisms of pregnancy complications in APS and provide a helpful instrument to all the workers in the field from both a clinical and basic view.

UR - http://www.scopus.com/inward/record.url?scp=84875955108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875955108&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-3194-7_5

DO - 10.1007/978-1-4614-3194-7_5

M3 - Chapter

AN - SCOPUS:84875955108

SN - 9781461431947

SN - 9781461431930

SP - 79

EP - 101

BT - Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies

PB - Springer US

ER -